Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.
Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Effects of beta-adrenergic stimulation on the acutely obstructed ureter in dogs. (1/44)

The objective of the present study was to evaluate the effects of a selective beta(3)-adrenoceptor agonist, (R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1, 3-benzodioxole-2,2-dicarboxylate (CL 316243), on the acutely obstructed ureter in anesthetized dogs. After a complete ureteral obstruction produced by the inflation of a balloon catheter placed within the left lower ureter, the intraluminal ureteral pressure gradually rose to reach a plateau of approximately 52.5 mm Hg. Intravenous administration of isoproterenol (a nonselective beta-adrenoceptor agonist; 10 microg/kg) and CL 316243 (1 microg/kg) significantly decreased this elevated ureteral pressure (by 74.1 and 77.2%, respectively), with the reduction more sustained with CL 316243 than with isoproterenol. In addition, under both isoproterenol and CL 316243, urine flow (which had been interrupted by the balloon) was resumed, resulting in further sustained decreases in ureteral pressure. The mean blood pressure decreased and heart rate increased after the administration of both drugs, but these changes were greater in the isoproterenol group than in the CL 316243 group. In contrast, i.v. administration of butylscopolamine (an anticholinergic agent; 1000 microg/kg) had no evident effects on ureteral pressure or on urine flow. The increase in left kidney weight seen after ureteral obstruction was suppressed by CL 316243. We conclude that the selective beta(3)-adrenoceptor agonist tested appears to be more useful than isoproterenol for reducing ureteral pressure above the obstructed site and for promoting ureteral relaxation and increasing urine flow around the point of obstruction in dogs.  (+info)

The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. (2/44)

The influence of synthetic drugs prescribed for peptic ulcer on the pharmacokinetic fate of glycyrrhizin (GL) from Shaoyao-Gancao-tang (SGT, a traditional Chinese formulation, Shakuyaku-Kanzo-to in Japanese) was investigated in rats. Co-administration of histamine H2-receptor antagonist (cimetidine) and anticholinergic drug (scopolamine butyl bromide) with SGT didn't influence the area under the plasma concentration-time curves (AUC) of glycyrrhetic acid (GA), an active metabolite derived from GL in SGT. The AUC of GA from SGT were significantly reduced by co-administration of synthetic drugs commonly used for peptic ulcer in a triple therapy (OAM), a combination of a proton pump inhibitor (omeprazole) and two antibiotics (amoxicillin and metronidazole). We found that the reduction of AUC in OAM treatment was due to the antibacterial effect of amoxicillin and metronidazole on intestinal bacteria in rat which lead to the decrease of GL-hydrolysis activity. The present study suggests that it may not be a proper way to use triple therapy containing antibiotics simultaneously with SGT for healing of chronic ulcers.  (+info)

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy--a comparative study with butyl scopolamine bromide. (3/44)

BACKGROUND: Glucagon inhibits digestive motility and is used for endoscopic premedication; however, its effect on cardiopulmonary function during endoscopy has not yet been fully investigated. AIM: To clarify the efficacy and safety of glucagon compared with butyl scopolamine bromide as upper gastrointestinal endoscopy premedication. METHODS: Two hundred and forty consecutive patients over 40 years of age, referred for upper gastrointestinal endoscopy, without any complications, were studied. These patients were randomly premedicated with butyl scopolamine bromide (SC group) or glucagon (G group). Time course changes in blood pressure, arterial oxygen saturation, heart rate and the number of retching episodes during endoscopy were examined. The efficacy of glucose tablets after upper gastrointestinal endoscopy to prevent hypoglycaemia caused by glucagon was evaluated. Cardiopulmonary parameters were also examined in 77 complicated patients with glucagon premedication (GC group). RESULTS: A continuous increase in heart rate during upper gastrointestinal endoscopy was observed in the SC group, but not in the G and GC groups. Blood pressure, arterial oxygen saturation and number of retching episodes were not different between the groups. Hypoglycaemia-related symptoms were frequent in the G group without glucose tablets, but were prevented by the administration of glucose. CONCLUSIONS: Glucagon has a weaker effect on cardiopulmonary function during upper gastrointestinal endoscopy than butyl scopolamine bromide. Glucose administration prevents hypoglycaemia-related symptoms caused by glucagon.  (+info)

Identification of the biomechanical factors associated with the perception of distension in the human esophagus. (4/44)

Current techniques used to investigate the mechanisms responsible for the sensory responses to distension of the human esophagus provide limited information because the degree of circumferential stretch required to determine tension can only be inferred. We used impedance planimetry to measure the cross-sectional area during esophageal distension to ascertain the degree of stretch and tension that initiated motor and sensory responses. Hyoscine-N-butyl bromide (HBB), a cholinergic muscarinic receptor blocker, was also used to alter esophageal tension during distension. Motor activity was initiated at a lower degree of stretch and tension than that which initiated sensory awareness; both increased directly with increasing distension. HBB reduced both esophageal motility and tension during distension without altering the relationship between sensation intensity and cross-sectional area. Esophageal stretch, rather than tension, thus appears to be the major factor influencing sensory responses to esophageal distension.  (+info)

Sensory and biomechanical responses to ramp-controlled distension of the human duodenum. (5/44)

The aim of this study was to develop a new method for investigation of the relationship among the mechanical stimulus, the biomechanical properties, and the visceral perception evoked by volume/ramp-controlled distension in the human duodenum in vivo. An impedance planimetric probe for balloon distension was placed in the third part of the duodenum in seven healthy volunteers. Distension of the duodenum was done at infusion rates of 10, 25, and 50 ml/min. The pump was reversed when level 7 was reached on a visual analog scale ranging from 0 to 10. Distensions were done with and without the administration of the antimuscarinic drug butylscopolamine. The total circumferential tension (T(total)) and the passive circumferential tension (T(passive)) were determined from the distension tests without and with the administration of butylscopolamine, respectively. T(total) and T(passive) showed an exponential behavior as a function of strain (a measure of deformation). The active circumferential tension (T(active)) was computed as T(total)-T(passive) and showed a bell-shaped behavior as a function of strain. At low distension intensities, the intensity of sensation at 10 ml/min was significantly higher than that obtained at 25 and 50 ml/min. The coefficient of variation at the pain threshold for circumferential strain (average 4.34) was closer to zero compared with those for volume (8.72), pressure (31.22), and circumferential tension (31.55). This suggests that the mechanoreceptors in the gastrointestinal wall depend primarily on circumferential strain. The stimulus-response functions provided evidence for the existence of low- and high-threshold mechanoreceptors in the human duodenum. Furthermore, the data suggest that high-threshold receptors are nonadapting.  (+info)

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Buscopan (hyoscine butylbromide) in abdominal colic. (6/44)

A short cut review was carried out to establish whether buscopan (hyoscine butylbromide) is better than analgesics at controlling pain in abdominal colic. A total of 31 papers were found using the reported search, of which none presented any evidence to answer the clinical question. It is concluded that there is no evidence available to answer this question. Further research is needed.  (+info)

Effect of diazepam and hyoscine butylbromide on response to secretin and cholecystokinin-pancreozymin in man. (7/44)

Ten subjects received secretin and cholecystokinin or, in duplicate tests, the two hormones together with either diazepam or diazepam plus hyoscine butylbromide in order to determine whether these drugs, which are often used during retrograde endoscopic cannulation of the pancreatic duct, affect pancreatic and biliary secretion in response to the hormones. Diazepam with hyoscine butylbromide reduced the secretion of trypsin into the duodenum and delayed the appearance of both trypsin and bilirubin in duodenal aspirate. These effects must be taken into account when interpreting pancreatic and biliary responses measured during direct cannulation of the pancreatic duct.  (+info)

Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. (8/44)

1. Twelve healthy subjects were enrolled in a double-blind placebo controlled cross-over study in order to assess the possible anticholinergic effects of four doses of a new antihistamine compound, mizolastine, compared with hyoscine butylbromide (HBB) used as a reference anticholinergic drug. 2. Although mizolastine, a potent and selective H1-receptor blocker has no affinity for muscarinic receptors and does not antagonize the effects of carbachol in rodents, a study was initiated to investigate its effects on various effectors possessing muscarinic receptors (eye, heart, sweat gland, salivary gland). 3. HBB (40 mg, s.c.) impaired accommodation, decreased salivary flow and inhibited cardiac sinus arrhythmia. Pupil diameter and maximum constriction speed, carbachol-induced skin sweating and Valsalva ratio were unaffected. 4. Mizolastine (5, 10, 20, 40 mg p.o.) did not affect any parameter at any time point, demonstrating a lack of anticholinergic effect.  (+info)

Butylscopolammonium Bromide is an anticholinergic drug, which is used as a smooth muscle relaxant and an anti-spasmodic agent. It works by blocking the action of acetylcholine, a neurotransmitter in the body, on certain types of receptors, leading to relaxation of smooth muscles and reduction of spasms.

This medication is commonly used to treat gastrointestinal disorders such as irritable bowel syndrome, intestinal cramps, and spastic constipation. It may also be used in the management of bladder disorders, including neurogenic bladder and urinary incontinence.

The drug is available in various forms, including tablets, suppositories, and solutions for injection. The dosage and route of administration depend on the specific condition being treated and the patient's overall health status. As with any medication, Butylscopolammonium Bromide can cause side effects, such as dry mouth, blurred vision, dizziness, and constipation. It should be used under the guidance of a healthcare professional to ensure safe and effective treatment.

In medical terms, "bromides" refer to salts or compounds that contain bromine, a chemical element. Historically, potassium bromide was used as a sedative and anticonvulsant in the 19th and early 20th centuries. However, its use has largely been discontinued due to side effects such as neurotoxicity and kidney damage.

In modern medical language, "bromides" can also refer to something that is unoriginal, dull, or lacking in creativity, often used to describe ideas or expressions that are trite or clich├ęd. This usage comes from the fact that bromide salts were once commonly used as a sedative and were associated with a lack of excitement or energy.

"Buscopan- n-butylscopolammonium bromide injection". DailyMed. 8 June 2020. Retrieved 16 October 2020. Tytgat GN (2007). " ... "Butylscopolamine bromide". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Articles with short ... The attachment of the butyl-bromide moiety effectively prevents the movement of this drug across the blood-brain barrier, ...
It was anything, Vitamin C, Scobutil (N-butylscopolammonium bromide), just to make them think that all will be good. My story ...
... butylscopolammonium bromide MeSH D03.132.889.848.661.550 - n-methylscopolamine MeSH D03.132.920.256 - cevanes MeSH D03.132. ... butylscopolammonium bromide MeSH D03.605.869.900.700.550 - n-methylscopolamine MeSH D03.661.243.320 - 4-hydroxyaminoquinoline-1 ... pyridostigmine bromide MeSH D03.383.725.762.760 - pyrithiamine MeSH D03.383.725.762.900 - trimedoxime MeSH D03.383.725.762.925 ...
"Buscopan- n-butylscopolammonium bromide injection". DailyMed. 8 June 2020. Retrieved 16 October 2020. Tytgat GN (2007). " ... "Butylscopolamine bromide". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Articles with short ... The attachment of the butyl-bromide moiety effectively prevents the movement of this drug across the blood-brain barrier, ...
Butylscopolammonium Bromide D2.145.74.722.900.700.200. D4.75.80.875.99.722.900.700.200. Butyrylthiocholine D2.886.489.789.200. ...
Butylscopolammonium Bromide D2.145.74.722.900.700.200. D4.75.80.875.99.722.900.700.200. Butyrylthiocholine D2.886.489.789.200. ...
Aged, Angiography, Digital Subtraction, Blood Pressure, Butylscopolammonium Bromide, Electrocardiography, Female, Heart Rate, ...
The analgesic effect of N-butylscopolammonium bromide (0.3 mg/kg) using a balloon-induced model of colic in ponies was ... A comparison of N-butylscopolammonium bromide and butorphanol tartrate for analgesia using a balloon model of abdominal pain in ... while 6 out of 8 ponies responded to N-butylscopolammonium bromide. There were no statistical differences in the CPS or ...
Technetium Tc 99m DisofeninButylscopolammonium BromideGastrointestinal AgentsTechnetium Tc 99m LidofeninAnti-Dyskinesia Agents ...
Butylscopolammonium Bromide D2.145.74.722.900.700.200. D4.75.80.875.99.722.900.700.200. Butyrylthiocholine D2.886.489.789.200. ...
Butylscopolammonium Bromide Actions. * Search in PubMed * Search in MeSH * Add to Search ...
... nausea and vomiting caused by malignant gastrointestinal obstruction octreotide showed the best and butylscopolammonium bromide ... Studies prove effectiveness of butylscopolammonium in the treatment of nausea and vomiting caused by malignant gastrointestinal ... obstruction, whereas octreotide is superior to butylscopolammonium. Regarding benzodiazepines for symptom control of nausea and ...
Butylscopolammonium Bromide Preferred Term Term UI T005920. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1976). ... N-Butylscopolammonium Bromide Term UI T005923. Date10/26/1981. LexicalTag NON. ThesaurusID UNK (19XX). ... Butylscopolammonium Bromide Preferred Concept UI. M0003107. Registry Number. 2Z3E1OF81V. Related Numbers. 149-64-4. Scope Note ... Butylscopolammonium Bromide. Tree Number(s). D02.092.877.310. D02.145.074.722.822.200. D03.132.889.601.200. D03.605.084.500. ...
Butylscopolammonium Bromide Preferred Term Term UI T005920. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1976). ... N-Butylscopolammonium Bromide Term UI T005923. Date10/26/1981. LexicalTag NON. ThesaurusID UNK (19XX). ... Butylscopolammonium Bromide Preferred Concept UI. M0003107. Registry Number. 2Z3E1OF81V. Related Numbers. 149-64-4. Scope Note ... Butylscopolammonium Bromide. Tree Number(s). D02.092.877.310. D02.145.074.722.822.200. D03.132.889.601.200. D03.605.084.500. ...
... butylscopolammonium bromide, E0300690,Buscolysin,butylscopolammonium bromide, E0300691,Buscopan,butylscopolammonium bromide, ...
Butylscopolammonium Bromide D2.145.74.722.900.700.200. D4.75.80.875.99.722.900.700.200. Butyrylthiocholine D2.886.489.789.200. ...
Butylene Glycols N0000166750 Butylhydroxybutylnitrosamine N0000179059 butylparaben N0000166994 Butylscopolammonium Bromide ... methylenedioxyamphetamine N0000170282 N-Methylaspartate N0000005877 N-Methylscopolamine N0000179341 N-Methylscopolamine Bromide ... Cyanates N0000008185 Cyanides N0000179093 cyanine green G base N0000171530 Cyanoacrylates N0000166199 Cyanogen Bromide ... Mesylate N0000007635 2-Chloroadenosine N0000179486 2-ethylhexyl salicylate N0000166603 2-Hydroxy-5-nitrobenzyl Bromide ...
C20.683.515.761.480.875.775.165 Butylscopolammonium Bromide D2.145.74.722.900.700.200 D4.75.80.875.99.722.900.700.200 ...

No FAQ available that match "butylscopolammonium bromide"